Literature DB >> 2619279

In vitro susceptibility of Nocardia spp. to a new fluoroquinolone, tosufloxacin (T-3262).

K Yazawa1, Y Mikami, J Uno.   

Abstract

The in vitro activity of a new fluoroquinolone, tosufloxacin (T-3262), against 111 pathogenic Nocardia strains was studied by an agar dilution method and compared with the activities of other fluoroquinolones. All strains were susceptible to tosufloxacin, and the drug was 2 to 20 times more active than four other quinolones tested. Nocardia farcinica was the Nocardia species most susceptible to tosufloxacin.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2619279      PMCID: PMC172836          DOI: 10.1128/AAC.33.12.2140

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

2.  Susceptibility of Nocardia asteroides to new quinolones and beta-lactams.

Authors:  M E Gombert; T M Aulicino; L duBouchet; L R Berkowitz
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

3.  In vitro susceptibilities of Nocardia species to newer antimicrobial agents.

Authors:  P Berkey; D Moore; K Rolston
Journal:  Antimicrob Agents Chemother       Date:  1988-07       Impact factor: 5.191

4.  Trimethoprim/sulfamethoxazole-resistant Nocardia asteroides causing multiple hepatic abscesses. Successful treatment with ampicillin, amikacin, and limited computed tomography-guided needle aspiration.

Authors:  F R Cockerill; R S Edson; G D Roberts; J C Waldorf
Journal:  Am J Med       Date:  1984-09       Impact factor: 4.965

5.  Lymphocutaneous nocardiosis caused by Nocardia asteroides. Case report and literature review.

Authors:  R Tsuboi; K Takamori; H Ogawa; Y Mikami; T Arai
Journal:  Arch Dermatol       Date:  1986-10

6.  Therapy of experimental cerebral nocardiosis with imipenem, amikacin, trimethoprim-sulfamethoxazole, and minocycline.

Authors:  M E Gombert; T M Aulicino; L duBouchet; G E Silverman; W M Sheinbaum
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

7.  Nocardial infections in the United States, 1972-1974.

Authors:  B L Beaman; J Burnside; B Edwards; W Causey
Journal:  J Infect Dis       Date:  1976-09       Impact factor: 5.226

8.  Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis.

Authors:  M Tsukamura; E Nakamura; S Yoshii; H Amano
Journal:  Am Rev Respir Dis       Date:  1985-03

9.  Numerical analysis of the taxonomy of Nocardiae and Rhodococci.

Authors:  M Tsukamura
Journal:  Microbiol Immunol       Date:  1982       Impact factor: 1.955

  9 in total
  3 in total

1.  Inactivation of rifampin by Nocardia brasiliensis.

Authors:  K Yazawa; Y Mikami; A Maeda; M Akao; N Morisaki; S Iwasaki
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

Review 2.  The medically important aerobic actinomycetes: epidemiology and microbiology.

Authors:  M M McNeil; J M Brown
Journal:  Clin Microbiol Rev       Date:  1994-07       Impact factor: 26.132

3.  Inactivation of the macrolide antibiotics erythromycin, midecamycin, and rokitamycin by pathogenic Nocardia species.

Authors:  K Yazawa; Y Mikami; T Sakamoto; Y Ueno; N Morisaki; S Iwasaki; K Furihata
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.